What is TB-500 best established for?

Actin sequestration: the recognised molecular function of its parent protein, and the activity the fragment's motif carries.

Is the wound-healing evidence about TB-500?

Largely about full-length thymosin beta-4. The distinction is routinely lost in secondary writing.

Is there human clinical evidence?

Limited. The literature is predominantly in vitro and animal work.

TB-500 Benefits and Studied Effects in the Literature

The short answer

Reported effects span actin sequestration, cell migration, angiogenesis, corneal wound healing and cardiac repair models. Actin sequestration is the best established and the most attributable to the fragment; the repair literature is more extensive and largely used full-length thymosin beta-4.

Key facts

Best established: G-actin sequestration
Well supported: Cell migration in vitro
Reported: Angiogenesis, corneal and cardiac repair
Dominant evidence type: In vitro and animal models
Compound in repair work: Largely full-length Tβ4
Human clinical data: Limited

Sorted by how well established

Actin sequestration is the firmest: it is the protein's recognised molecular function, mechanistically characterised, and the fragment carries the motif associated with it. Cell migration follows, with a short mechanistic route from actin and consistent in vitro results. Angiogenesis and tissue repair are more distant. These are real reported findings, but with longer causal chains and more dependence on the specific model.

The corneal work

Sosne and colleagues reported in Experimental Eye Research in 2002 that thymosin beta-4 promotes corneal wound healing and decreases inflammation in an animal model. The cornea is a useful system for wound work (accessible, avascular, and easy to image), and this is among the more frequently cited findings in the field. It used the protein.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

The cardiac work

Shrivastava and colleagues reviewed thymosin beta-4 and cardiac repair in the Annals of the New York Academy of Sciences in 2010. Cardiac repair attracted substantial interest because the heart regenerates poorly, making any candidate promoting repair notable. Again, the protein.

The pattern worth noticing

The findings that make TB-500 interesting commercially (wound healing, tissue repair, cardiac regeneration) are largely findings about thymosin beta-4. The findings most attributable to TB-500 itself are the molecular ones. That inversion is the single most useful thing to hold in mind when reading marketing material about this compound.

What is absent

Substantial human clinical data. Registered interventional trials of the heptapeptide. Independent confirmation that the fragment reproduces the protein's repair effects. None of these absences refutes anything; together they mark where the evidence stops.

Frequently asked questions

What is TB-500 best established for?: Actin sequestration: the recognised molecular function of its parent protein, and the activity the fragment's motif carries.
Is the wound-healing evidence about TB-500?: Largely about full-length thymosin beta-4. The distinction is routinely lost in secondary writing.
Is there human clinical evidence?: Limited. The literature is predominantly in vitro and animal work.

Extended research context

The TB-500 (Thymosin β4 fragment) deep dive

Deep dive: TB-500 vs full-length Thymosin Beta-4

'TB-500' is a synthetic peptide corresponding to the active 17-amino-acid actin-binding region of the endogenous 43-residue Thymosin Beta-4 protein. The two are not identical. TB-500 lacks the flanking sequence that gives full-length TB-4 additional binding partners. In the research literature, papers use 'Thymosin β4' when they mean the full protein and 'TB-500' or 'AcSDKP fragment' when they mean the shorter synthetic peptide. Reading a CoA carefully to see which molecule is in the vial matters. Mass spec is the definitive check.

Actin-binding as the core mechanism

The N-terminal region of TB-4 (and TB-500 by inheritance) contains the canonical actin-binding motif. This motif sequesters G-actin monomers, modulating the G:F actin equilibrium in cell cultures. That mechanism is why almost every mechanistic paper on TB-500 traces back to cytoskeletal reorganisation, cell migration, and models of tissue repair.

Handling considerations unique to TB-500

TB-500 is a 17-residue peptide with modest amphipathicity; it reconstitutes cleanly in bacteriostatic water but is sensitive to repeated freeze/thaw. Aliquoting into single-use volumes on first reconstitution preserves potency across a batch. HPLC on the batch CoA should show a single dominant peak; a doublet suggests deamidation.

Research applications

▸In vitro actin-polymerisation assays (G:F actin ratio measurement)
▸Cell-migration and wound-scratch assays in fibroblast lines
▸Angiogenesis models: tube-formation and endothelial migration assays
▸Analytical method development for short peptides on RP-HPLC
▸Reference-material comparisons against endogenous Thymosin β4

Handling checklist

✓Store lyophilised vials at −20 °C long-term
✓Reconstitute with bacteriostatic water (0.9% benzyl alcohol)
✓Aliquot immediately to avoid freeze/thaw cycles
✓Refrigerate reconstituted aliquots at 2–8 °C; use within 28 days
✓Confirm mass (~4,963 Da for TB-500) via CoA before study use

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Assuming TB-500 = full Thymosin β4

Fix: TB-500 is the 17-residue actin-binding fragment; check the CoA sequence.

✗ Repeated freeze/thaw

Fix: Aliquot at first reconstitution; each cycle degrades yield.

✗ Using tap water

Fix: Use bacteriostatic or sterile water only.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More TB-500 (Thymosin β4 fragment) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

TB-500 Benefits: What Is Established and What Is Not